The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.
May 20th 2024
On May 20, 2024, the FDA announced the approval of 2 products as interchangeable biosimilars to aflibercept—the first products to receive such a designation from the FDA.
The Role of Faricimab in Treatment of AMD, DME
July 15th 2022Carl D. Regillo, MD, FACS; and David R. Lally, MD, discuss the recent FDA approval of faricimab and the potential impact of having a molecule that inhibits 2 pathways that play a role in diabetic macular edema and neovascularization in the treatment armamentarium.
Considerations for Using Anti-VEGF Agents in AMD, DME
July 15th 2022Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, consider the implications of real-world evidence indicating fewer visual gains associated with anti-VEGF therapies compared with clinical trials.